Actively Recruiting
Low Dose Whole Lung Radiation Therapy for Patients With COVID-19 and Respiratory Compromise
Led by Ohio State University Comprehensive Cancer Center · Updated on 2021-03-15
24
Participants Needed
1
Research Sites
75 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Low doses of radiation in the form of chest X-rays have been used to treat people with pneumonia. This treatment was found to be effective by reducing inflammation and with minimal side effects. However, it was an expensive treatment and was eventually replaced with less costly treatments such as antibiotics. Radiation has also been shown in some animal experiments to reduce some types of inflammation. Some patients diagnosed with COVID-19 pneumonia will experience worsening disease, which can become very serious, requiring the use of a ventilator. This is caused by inflammation in the lung from the virus and the immune system. For this study, the x-ray given is called radiation therapy. Radiation therapy uses high-energy X-ray beams from a large machine to target the lungs and reduce inflammation. Usually, it is given at much higher doses to treat cancers. The purpose of this study is to find out if adding a single treatment of low-dose x-rays to the lungs might reduce the amount of inflammation in the lungs from a COVID-19 infection, which could help a patient to breathe without use of a ventilator.
CONDITIONS
Official Title
Low Dose Whole Lung Radiation Therapy for Patients With COVID-19 and Respiratory Compromise
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Laboratory diagnosis of COVID-19 within 14 days of enrollment
- CT or X-ray findings typical of COVID-19 pneumonia within 5 days of enrollment
- Receiving mechanical ventilation in an intensive care unit (ICU)
- Life expectancy of at least 24 hours as judged by the investigator
- Hypoxemia with Pa/FIO2 ratio less than 300 or SpO2/FiO2 less than 315
- Signed informed consent by the patient or legal representative
You will not qualify if you...
- Moribund with expected survival less than 24 hours
- Expected survival less than 30 days due to chronic illness prior to COVID-19 infection
- Not committed to full disease-specific therapy (comfort care allowed)
- Treatment with immune suppressing medications within the last 30 days (except steroids for ARDS or septic shock)
- COVID-19 illness presumed longer than 14 days
- Hospital admission longer than 14 days
- Deemed unsafe for travel for radiation therapy
- Chronic hypoxemia requiring supplemental oxygen at baseline
- Active connective tissue disease (e.g., scleroderma) or idiopathic pulmonary fibrosis
- Prior radiation therapy causing grade 2 or higher radiation pneumonitis within 365 days
- Radiation to the chest within 180 days (except skin-only treatments)
- Known active uncontrolled bacterial or fungal lung infections
- Active cytotoxic chemotherapy
- Females who are pregnant or have a positive pregnancy test
- Breastfeeding
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center
Columbus, Ohio, United States, 43210
Actively Recruiting
Research Team
A
Arnab Chakravarti
CONTACT
K
Kimberly Mahler
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here